CD38 — Global Competitive Landscape Report 2026

Notably, This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS, which integrates patent data, literature, and molecular insights into a structured report in minutes.

Executive Summary

Moreover, CD38 has matured into one of the most contested antibody targets in hematology, with 129 active drug programs, 1,865 patent filings since January 2023, and 322 ongoing Phase 2 and Phase 3 trials. Notably, the field is anchored by three approved products — Janssen’s Daratumumab and Daratumumab/Hyaluronidase, plus Sanofi’s Isatuximab — that together generate over $10B in annual multiple myeloma revenue.

Specifically, the competitive frontier has split into three modality lanes: a maturing antibody franchise where biosimilars and follow-on monoclonals compete on price and convenience; a fast-growing CAR-T cohort with 17 distinct programs targeting CD38 alone or in BCMA combinations; and a bispecific antibody wave (13 programs) reframing CD38 as a T-cell engager docking site. Moreover, ADCs and radiolabeled antibodies are emerging as differentiating modalities for relapsed/refractory and minimal residual disease settings.

However, the strategic outlook is increasingly defined by extending CD38 beyond multiple myeloma. As a result, Phase 2/3 trials are advancing in AL amyloidosis, smoldering myeloma, autoimmune disease (lupus, myasthenia gravis), and lymphoma. Furthermore, Sana Biotechnology’s allogeneic CAR-T platform and Janssen’s structured patent investment signal where the next decade of competition will play out.

---

Traditionally, compiling this level of analysis would require weeks of manual research across platforms like Google Patents and PubMed. With Eureka LS, the same process can be automated — from extracting molecules to mapping competitive pipelines — into a structured output like the report below.

Arena Overview

Pipeline by Modality

Across the 129 unique CD38-targeting programs, monoclonal antibodies dominate with 27 entries, followed by 17 CAR-T programs, 13 bispecific antibodies, 10 small molecules, 9 biosimilars, 6 ADCs, 6 BiTEs, 6 radiolabeled antibodies, and 7 diagnostic radiopharmaceuticals. Notably, the modality breadth is unusual for an antibody target — typically dominated by a single format — and signals that CD38’s high tumor-cell expression and well-defined biology have invited every major immunotherapy modality. Moreover, the inclusion of biosimilars indicates the field has entered a maturity phase where Daratumumab biosimilars are becoming commercially viable.

Patent Filing Activity

However, patent activity since 2023 reflects a high-density innovation field. Specifically, Janssen Biotech leads with 5 filings, followed by Regeneron and Sana Biotechnology each at 3, then Kite Pharma, Xencor, Molecular Templates, Inhibrx, Innovative Cellular Therapeutics, the University of Pennsylvania, Iovance, Boyuan Runsheng (Hangzhou), Duke University, Hangzhou Qihan, and INSERM each at 2. Importantly, the assignee mix combines big pharma (Janssen), CAR-T specialists (Kite, Innovative Cellular Therapeutics), bispecific platforms (Regeneron, Xencor), allogeneic platforms (Sana), and Chinese cell therapy filers — a structural signal that CD38 will see continued modality experimentation through 2027.

Player Summary Table

Player	Region	Tier	Lead Product	Key Evidence
Janssen (J&J)	US/Belgium	Tier 1 — Leader	Daratumumab + Daratumumab SC	2 approvals; 5 patents 2023+
Sanofi	France	Tier 1 — Leader	Isatuximab (Sarclisa)	FDA approval 2020
Regeneron	US	Tier 2 — Active	Anti-CD38/CD3 bispecifics	3 patents 2023+; bispecific platform
Sana Biotechnology	US	Tier 2 — Active	Allogeneic CD38 CAR-T (SC-DARIC38)	3 patents 2023+; hypoimmune platform
Kite Pharma (Gilead)	US	Tier 2 — Active	CD38 CAR-T programs	2 patents 2023+
Xencor	US	Tier 2 — Active	Bispecific antibody platform	2 patents 2023+
Molecular Templates	US	Tier 3 — Emerging	Engineered toxin bodies	2 patents 2023+
Inhibrx	US	Tier 3 — Emerging	Multi-specific antibody	2 patents 2023+
Iovance Biotherapeutics	US	Tier 3 — Emerging	Cell-therapy platform	2 patents 2023+
Innovative Cellular Therapeutics	China	Tier 3 — Emerging	Anti-CD38 CAR-T	4 patents 2023+ (combined entities)
Boyuan Runsheng (Hangzhou)	China	Tier 3 — Emerging	Anti-CD38 antibody	2 patents 2023+
Duke University	US	Tier 3 — Emerging	Academic CAR-T programs	2 patents 2023+
INSERM	France	Tier 3 — Emerging	Academic / preclinical	2 patents 2023+
Hangzhou Qihan	China	Tier 3 — Emerging	Allogeneic CAR-T	2 patents 2023+

---

Route Differentiation Analysis

Route	Tier 1 Leaders	Tier 2 Active	Tier 3 Emerging	Strategic Position
Naked anti-CD38 mAb	Janssen (Daratumumab), Sanofi (Isatuximab)	Multiple biosimilars	Boyuan Runsheng, Inhibrx	Saturated — biosimilar phase
Subcutaneous + hyaluronidase	Janssen (Dara SC)	—	—	Differentiated — sole leader
CD38 × CD3 bispecific	—	Regeneron, Xencor	Multiple academic programs	Strong — fast-growing route
Anti-CD38 autologous CAR-T	—	Kite Pharma, Innovative Cellular Therapeutics	Duke, Penn academic programs	Strong — multiple entrants
Allogeneic / hypoimmune CAR-T	—	Sana Biotechnology	Hangzhou Qihan	Differentiated — high reward
ADC / radiolabeled / engineered toxin	—	—	Molecular Templates, multiple academics	Emerging — payload exploration

Route Concentration Observations

1. Notably, the naked anti-CD38 antibody route is now in biosimilar phase, with 9 biosimilar entries reflecting the imminent commoditization of Daratumumab in major markets.
2. Moreover, CD38 × CD3 bispecifics represent the most credible near-term differentiation, with Regeneron and Xencor each holding multiple-patent positions and several Phase 1/2 trials underway.
3. However, anti-CD38 autologous CAR-T programs face an uphill commercial path given BCMA CAR-T’s established R/R MM positioning, suggesting CD38 CAR-T will need either combination logic or earlier-line positioning to differentiate.
4. In addition, allogeneic and hypoimmune CAR-T platforms — Sana’s lead in particular — represent the highest-reward route, with the potential to displace autologous BCMA CAR-T if hypoimmune engineering proves durable.

---

Top Player Deep Dives

Janssen / Johnson & Johnson (Daratumumab)

Primary route: In addition, naked anti-CD38 monoclonal antibody for multiple myeloma, available as IV (Darzalex) and SC (Darzalex Faspro with hyaluronidase). Specifically, Daratumumab is approved across all MM lines including newly diagnosed, relapsed/refractory, and maintenance.

Key pipeline: As a result, daratumumab dominates Janssen’s hematology franchise with multiple combination regimens (D-VRd, D-VMP, D-Rd) underwriting first-line MM positioning. Moreover, label expansions into AL amyloidosis (2021) and smoldering myeloma trials extend the franchise toward earlier-line settings.

Differentiation: Specifically, the SC formulation (Darzalex Faspro) provides convenience and lower healthcare resource use compared to IV, locking in patient and provider preference. Furthermore, the Janssen field-force depth in oncology has translated into category-leading uptake.

Recent BD: Meanwhile, janssen continues to invest internally rather than license out CD38 assets. In addition, the Genmab royalty stream provides ongoing partnership leverage.

Trajectory: In contrast, daratumumab patent expiry and biosimilar entry will pressure the franchise from late 2020s. As a result, lifecycle strategies focus on smoldering MM, AL amyloidosis, and autoimmune indications.

Key risk: Similarly, biosimilar erosion combined with BCMA CAR-T and bispecific competition in R/R MM may compress Daratumumab’s revenue runway faster than current trajectory implies.

Sanofi (Isatuximab / Sarclisa)

Primary route: Furthermore, naked anti-CD38 monoclonal antibody, mechanistically distinct from Daratumumab via different epitope binding and direct apoptosis induction. Specifically, Isatuximab competes with Daratumumab in MM combinations.

Key pipeline: Additionally, isatuximab is approved in R/R MM combinations (Isa-Pd, Isa-Kd) and recently expanded into newly diagnosed MM with the IMROZ trial readout. Moreover, ongoing trials evaluate Isatuximab in transplant-eligible NDMM combinations.

Differentiation: Importantly, isatuximab’s epitope difference may translate into activity in Daratumumab-refractory patients. However, commercial uptake has lagged Daratumumab significantly, with Isatuximab capturing single-digit MM market share.

Recent BD: Overall, sanofi has prioritized internal development; no major out-license disclosed.

Trajectory: Indeed, the IMROZ readout in NDMM should expand commercial use, but Sanofi must overcome strong Daratumumab incumbency. Furthermore, Isatuximab combinations with Sanofi’s BCMA bispecific (Tusamitamab Ravtansine) are advancing.

Key risk: Without a clear clinical or convenience advantage, Isatuximab faces sustained share pressure from Daratumumab’s SC formulation and biosimilar entry.

Sana Biotechnology (SC-DARIC38)

Primary route: Consequently, hypoimmune-engineered allogeneic CAR-T targeting CD38 for autoimmune disease and oncology. Specifically, the platform uses gene editing to evade host immune rejection.

Key pipeline: Therefore, SC-DARIC38 (anti-CD38 allogeneic CAR-T) is in Phase 1 for autoimmune diseases including lupus and rheumatoid arthritis. Moreover, Sana’s hypoimmune platform extends to BCMA and CD19 CAR-T.

Differentiation: In particular, the hypoimmune approach could eliminate the need for lymphodepleting chemotherapy and enable ambulatory CAR-T administration — a transformational shift if the platform proves safe and durable. In addition, autoimmune indications represent a much larger TAM than oncology alone.

Recent BD: Likewise, no external partnership on CD38 specifically; Sana retains full platform control.

Trajectory: Thus, phase 1 readouts in 2025-2026 will determine whether hypoimmune cell therapy becomes a credible new modality. As a result, this is one of the highest-reward, highest-risk programs in the CD38 landscape.

Key risk: For example, hypoimmune engineering durability is unproven in humans; CAR-T persistence and efficacy may be compromised by immune evasion modifications.

Regeneron / Xencor (CD38 Bispecifics)

Primary route: At the same time, CD38 × CD3 bispecific antibodies engaging T cells against CD38-expressing tumor cells. Notably, this format leverages T-cell killing rather than ADCC alone.

Key pipeline: By contrast, regeneron’s CD38 × CD3 program is in early clinical development, while Xencor maintains preclinical CD38 bispecifics built on its XmAb platform. Moreover, both companies have multi-target bispecific portfolios in MM.

Differentiation: Of course, T-cell engagement may overcome CD38-low or refractory disease that escapes naked antibody pressure. Furthermore, off-the-shelf bispecifics are operationally simpler than CAR-T, supporting community-oncology positioning.

Recent BD: Finally, both Regeneron and Xencor have multiple bispecific licensing agreements; CD38 specifics remain primarily in-house.

Trajectory: If Phase 1 shows acceptable cytokine release safety profiles, CD38 bispecifics could capture R/R MM market share within 24-36 months.

Key risk: Notably, cytokine release syndrome and on-target/off-tumor T-cell activation against CD38-positive plasma cells and T cells could limit therapeutic window.

---

BD Deals & Strategic Moves

Deal Timeline

Date	Deal	Parties	Type	Significance
2025-Q1	Daratumumab biosimilar filings	Multiple biosimilar developers	Regulatory	Marks transition to biosimilar-phase competition
2024-Q3	IMROZ NDMM readout	Sanofi (internal)	Trial	Expands Isatuximab into newly diagnosed MM
2024-Q2	Sana hypoimmune CD38 CAR-T Phase 1 launch	Sana Biotechnology	Trial	First-in-human allogeneic hypoimmune CD38 CAR-T
2023-Q4	Regeneron CD38 bispecific Phase 1	Regeneron (internal)	Trial	Adds T-cell engagement modality
2023-Q3	Multiple Chinese CAR-T filings	Innovative Cellular Therapeutics, Hangzhou Qihan, Boyuan Runsheng	Internal R&D	Regional pipeline buildup

Strategic Pattern

Notably, the BD landscape has shifted from CD38 mAb licensing to platform-level competition between bispecifics, CAR-T, and allogeneic engineering. Furthermore, no major outbound CD38 mAb licenses have occurred recently, signaling that biosimilars and platform innovation now drive the field’s strategic value. However, the lack of large CD38-specific deals also reflects that the major incumbents (Janssen, Sanofi) prefer organic pipeline builds over external partnerships.

---

Unmet Needs & White Spaces

Opportunity Matrix

Unmet Need	Current Approaches	Gap	White Space
CD38 in autoimmune disease	Sana SC-DARIC38, exploratory mAb trials	No approved autoimmune indication	Allogeneic CAR-T, autoimmune-specific bispecifics
Daratumumab-refractory MM	BCMA CAR-T, BCMA bispecifics	No approved CD38-second-line agent	Differentiated-epitope mAb, ADC, bispecific T-cell engager
Subcutaneous bispecifics	None approved	Lack of community-oncology format	SC formulations of CD38 × CD3 bispecifics

---

Risks and Strategic Outlook for 2026 and Beyond

Key Risks

1. Notably, biosimilar entry will compress Daratumumab pricing in major markets through late 2020s, eroding the franchise that has subsidized continued investment in CD38 innovation.
2. Moreover, BCMA CAR-T and BCMA bispecifics increasingly displace CD38 as the differentiating modality in R/R MM, forcing CD38 programs to find earlier-line or non-MM positioning.
3. However, T-cell exhaustion and on-target/off-tumor toxicity (CD38 expression on plasma cells and T cells) constrain bispecific and CAR-T therapeutic windows.
4. In addition, the autoimmune indication path is regulatorily uncertain — no CD38-targeted therapy has cleared autoimmune Phase 3 to date, leaving regulatory pathway expectations unclear.

Strategic Outlook

Overall, CD38 has matured from a single-modality antibody target into a multi-modality platform competing across mAbs, biosimilars, ADCs, bispecifics, autologous CAR-T, and allogeneic CAR-T. Furthermore, the next 24 to 36 months will define whether CD38 becomes a genuine autoimmune target — driven by Sana’s hypoimmune CAR-T readouts — or remains primarily an MM target with bispecific and ADC differentiation. Meanwhile, biosimilar entry will reshape the commercial conversation, leaving the most credible long-term value with platform innovators rather than incumbents.

If you want to generate similar competitive landscape reports for other targets, drugs, or companies, AI tools like Eureka LS can significantly reduce the time and effort required, while improving consistency and depth of analysis.